AbbVie gains FDA approval for EPKINLY in follicular lymphoma

27 Jun 2024
·
Deals
www.pharmaceutical-technology.com
Drug ApprovalClinical ResultAccelerated ApprovalCell Therapy
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
Preview
Source: Pharmaceutical Technology
An overall response rate of 82% was seen in relapsed or refractory follicular lymphoma patients treated with the asset. Credit: Lightspring / Shutterstock.
AbbVie has announced accelerated approval from the US Food and Drug Administration (FDA) for EPKINLY (epcoritamab-bysp) to treat adult patients with relapsed or refractory follicular lymphoma  (R/R FL).
A T-cell engaging bispecific antibody for subcutaneous administration, EPKINLY is indicated for R/R FL patients following treatment with two or more lines of previous therapy.
The approval is based on the overall response rate and response durability elicited by the trial asset. Continued approval will follow on the regulator validating the clinical benefit of the antibody in a confirmatory trial(s).
Developed jointly by AbbVie and Genmab in a oncology partnership, epcoritamab will be commercialised by the parties in the US and Japan.
AbbVie will manage global commercialisation of the asset.
See Also:AstraZeneca’s Tagrisso receives approval in Japan for lung cancer
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
Preview
Source: Pharmaceutical Technology
AstraZeneca’s Truqap and Faslodex combo receives approval in EU
AbbVie gains FDA approval for EPKINLY in follicular lymphoma
Preview
Source: Pharmaceutical Technology
The FDA’s decision is based on the Phase I/II EPCORE NHL-1 clinical trial, which assessed EPKINLY’s safety and efficacy in 127 patients with a median of three previous therapies, 70% of whom had double refractory disease.
According to the findings, an overall % response rate of 82% was seen in subjects treated with EPKINLY, the trial’s primary endpoint. 60% experienced a complete response while 22% had a partial response.
At a median 14.8-month follow-up, the median duration of response had not been reached while sustained efficacy was observed in more than half of the responding patients.
Injection site reactions, cytokine release syndrome and Covid-19 were among the most common adverse reactions reported in the trial.
AbbVie haematology therapeutic area head and vice-president Mariana Cota Stirner stated: “EPKINLY treatment has shown deep and durable responses for many patients. Subcutaneous dosing offers convenience, and EPKINLY can be given to patients without mandatory hospitalisation using a three-step-up dosing regimen.
“We believe that EPKINLY has the potential to be a core therapy in the treatment of multiple B-cell malignancies and furthers our company mission to advance research to raise standards of care for patients with cancer.”
The latest development comes after the US FDA issued a complete response letter for the new drug application of AbbVie’s ABBV-951 to treat motor fluctuations in adult patients with advanced Parkinson’s disease.
For more details,please visit the original website
The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.
Organizations
Indications
Targets
-
Drugs
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.